1-氟-2-硝基-3-(三氟甲基)苯 | 1214335-98-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-氟-2-硝基-3-(三氟甲基)苯
• 中文别名: 1-氟-2-硝基-3-三氟甲基苯
• 英文名称: 1-fluoro-2-nitro-3-(trifluoromethyl)benzene
• CAS: 1214335-98-4
• 化学式: C₇H₃F₄NO₂
• 分子量: 209.1
• InChiKey: GZNQDXJGTLXDGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-氟-2-硝基-3-(三氟甲基)苯 在 盐酸 、 potassium carbonate 、 tin(ll) chloride 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 30.0h， 生成 C₁₉H₁₄ClF₄N₃
  参考文献：
  名称：

  Fragment Based Optimization of Metabotropic Glutamate Receptor 2 (mGluR2) Positive Allosteric Modulators in the Absence of Structural Information

  摘要：

  Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulators (PAMs) have been implicated as potential pharmacotherapy for psychiatric conditions. Screening our corporate compound deck, we identified a benzotriazole fragment (4) that was rapidly optimized to a potent and metabolically stable early lead (16). The highly lipophilic character of 16, together with its limited solubility, permeability, and high protein binding, however, did not allow reaching of the proof of concept in vivo. Since further attempts on the optimization of druglike properties were unsuccessful, the original hit 4 has been revisited and was optimized following the principles of fragment based drug discovery (FBDD). Lacking structural information on the receptor ligand complex, we implemented a group efficiency (GE) based strategy and identified a new fragment like lead (60) with more balanced profile. Significant improvement achieved on the druglike properties nominated the compound for in vivo proof of concept studies that revealed the chemotype being a promising PAM lead targeting mGluR2 receptors.

  DOI：

  10.1021/acs.jmedchem.8b00161

文献信息

• [EN] 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE ET DE 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE DE C-MYC ET P300/CBP POUR LE TRAITEMENT DU CANCER
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019049061A1

  公开（公告）日：2019-03-14

  The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity & nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的5-(1H-苯并[d]咪唑-2-基)-吡啶-2-胺和5-(3H-咪唑[4,5-b]吡啶-6-基)-吡啶-2-胺衍生物。具体而言，本发明涉及根据公式(lb)的化合物，其中R'、R2'、R3'、R4'、Rs'、R6'、R7'和X1'按本说明书中定义；或其盐，包括药用可接受的盐。本发明的化合物能够降低细胞中的MYC蛋白（c-MYC）和/或抑制p300/CBP组蛋白乙酰转移酶，可用于治疗心肌肥大、糖尿病、肥胖和非酒精性脂肪肝疾病、HIV、多囊肾疾病、炎症性疾病、强直性脊柱炎、银屑病、银屑病关节炎、类风湿性关节炎、克罗恩病、多发性硬化症、癌症和前癌症综合症，以及与Myc失调或p300/CBP组蛋白乙酰转移酶抑制相关的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步公开了使用本发明的化合物或包含本发明化合物的药物组合物，降低细胞中MYC蛋白（c-MYC）和抑制p300/CBP组蛋白乙酰转移酶活性的方法，以及治疗与之相关的疾病的方法。
• [EN] DISACCHARIDES FOR DRUG DISCOVERY<br/>[FR] DISACCHARIDES POUR LA DECOUVERTE DE MEDICAMENTS
  申请人：ALCHEMIA PTY LTD

  公开号：WO2003093286A1

  公开（公告）日：2003-11-13

  Methods are described for the preparation of combinatorial libraries of potentially biologically active disaccharide compounds. These compounds are variously functionalized, with a view to varying lipid solubility size, function and other properties, with the particular aim of discovering novel drug or drug-like compounds, or compounds with useful properties. The invention provides intermediates, processes and synthetic strategies for the solution or solid phase synthesis of disaccharides, variously functionalised about the sugar ring, including the addition of aromaticity and charge, and the placement of pharmaceutically useful groups and isosteres.

  描述了制备可能具有生物活性的二糖化合物组合库的方法。这些化合物通过各种方式进行了官能化，以改变脂溶性、大小、功能和其他性质，特别是为了发现新型的药物或类似药物化合物，或者具有有用性质的化合物。该发明提供了中间体、过程和合成策略，用于二糖的溶液或固相合成，包括在糖环周围进行不同的官能化，引入芳香性和电荷，以及放置药物上有用的基团和等电子体。
• [EN] IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS<br/>[FR] DÉRIVÉS D'IMINOTÉTRAHYDROPYRIMIDINONE UTILISÉS COMME INHIBITEURS DE PLASMEPSINE V
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2017089453A1

  公开（公告）日：2017-06-01

  A series of 2-imino-6-methyltetrahydropyrimidin-4(lH)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

  一系列在6-位置被苯基取代的2-亚氨基-6-甲基四氢嘧啶-4(1H)-酮衍生物，该苯基再通过一个可选取代的不饱和融合双环环系统进行间位取代，该环系统含有至少一个氮原子，作为血液型质体蛋白酶V活性的选择性抑制剂，对于药物制剂特别有益，尤其在治疗疟疾方面。
• Chiral linker-bridged bis-N-heterocyclic carbenes: design, synthesis, palladium complexes, and catalytic properties
  作者：Dao Zhang、Yu He、Junkai Tang

  DOI：10.1039/c6dt00984k

  日期：——

  2R)-diphenylethylene and (aR)-binaphthylene linkers have been designed and synthesized in 30–94% yield. Ten chiral bis(NHC) palladium complexes 20–28 have been synthesized and characterized by NMR, HRMS, elemental analysis and further confirmed by X-ray single crystal analysis. These bis(NHC)-Pd complexes showed obviously different catalytic properties in the asymmetric Suzuki–Miyaura coupling reactions. The

  已设计和合成了一系列手性双（苯并咪唑鎓）盐10–19与（1 R，2 R）-环己烯，（1 R，2 R）-二苯基乙烯和（a R）-联萘连接基屈服。已经合成了十种手性双（NHC）钯配合物20-28，并通过NMR，HRMS，元素分析和表征，并通过X射线单晶分析进一步证实。这些双（NHC）-Pd配合物在不对称的Suzuki-Miyaura偶联反应中显示出明显不同的催化性能。（1 R，2 R）-环己烯桥联的bis（NHC）-Pd络合物，（R，R）-图23的化合物的最高收率达到90％，而具有联萘连接基的配合物（A R）-28显示出最佳的对映选择性为60ee％。这些配合物的结构分析表明，这种催化性能的差异与其在金属中心周围的配位环境密切相关。
• HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME
  申请人：Generos Biopharma Ltd.

  公开号：EP3960736A1

  公开（公告）日：2022-03-02

  A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

  由式XI表示的杂环化合物，其药用盐、溶剂合物，或其药用盐的溶剂合物，以及其用途和含有该化合物的组合物。该化合物在结构上是新颖的，并具有良好的STAT5抑制活性。